388 related articles for article (PubMed ID: 32902560)
1. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
[TBL] [Abstract][Full Text] [Related]
3. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
4. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
5. Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Feng X; Berklein F; Rane PB; Habib M; Lin PJ
Cardiovasc Drugs Ther; 2021 Oct; 35(5):965-973. PubMed ID: 32594283
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
7. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
[TBL] [Abstract][Full Text] [Related]
8. Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability.
Buckley LF; Ting C; Fatani N; Fanikos J
J Clin Lipidol; 2020; 14(3):315-321.e4. PubMed ID: 32362514
[TBL] [Abstract][Full Text] [Related]
9. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
10. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
11. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
12. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
13. Spending and Utilization on Drugs Prescribed by Otolaryngologists to Medicare Beneficiaries, 2013 to 2017.
Shah SA; Miller LE; Xiao R; Workman A; Xu L; Rathi VK
Ann Otol Rhinol Laryngol; 2022 Sep; 131(9):987-996. PubMed ID: 34628959
[TBL] [Abstract][Full Text] [Related]
14. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
15. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
[TBL] [Abstract][Full Text] [Related]
16. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
18. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
19. Impact of formulary restrictions on medication use and costs.
Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
